RARE Earnings & Financial Statements
Ultragenyx Pharmaceutical Inc.
$14.90
-$0.02(-0.13%)
33
Overall
40
Value
10
Tech
50
Quality
Market Cap
$1.47B
Volume
2.96M
52W Range
$12.73 - $39.89
Target Price
$26.20
RARE earnings and financial statements: Ultragenyx Pharmaceutical Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
RARE Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $673.00M | $560.00M | $434.25M | $363.33M | $351.41M |
| Cost of revenue | $109.00M | $76.73M | $45.21M | $28.32M | $16.01M |
| Operating income | -$535.00M | -$536.00M | -$569.21M | -$648.92M | -$381.74M |
| EBITDA | -$536.00M | -$531.00M | -$582.46M | -$640.49M | -$410.32M |
| Net income | -$575.00M | -$569.00M | -$606.64M | -$707.42M | -$454.02M |
| EPS (diluted) | $-5.83 | $-6.29 | $-8.25 | $-10.12 | $-6.70 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $1.53B | $1.50B | $1.49B | $1.55B | $1.52B |
| Total liabilities | $1.60B | $1.24B | $1.22B | $1.19B | $599.84M |
| Shareholders’ equity | -$80.00M | $255.00M | $275.41M | $352.49M | $922.56M |
| Cash and equivalents | $421.00M | $174.00M | $213.58M | $132.94M | $307.58M |
| Long-term debt | $24.00M | $30.00M | $30.57M | - | - |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$466.00M | -$414.00M | -$474.81M | -$380.46M | -$338.69M |
| Capital expenditure | -$21.00M | -$20.00M | -$46.77M | -$146.12M | -$73.09M |
| Free cash flow | -$487.00M | -$434.00M | -$521.57M | -$526.59M | -$411.79M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | RARE | $14.90 | -0.1% | 2.96M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Ultragenyx Pharmaceutical Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW